Salix Pharmaceuticals Company Profile (NASDAQ:SLXP)

Analyst Ratings

Consensus Ratings for Salix Pharmaceuticals (NASDAQ:SLXP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Salix Pharmaceuticals (NASDAQ:SLXP)
Show:
DateFirmActionRatingPrice TargetActions
3/18/2015Jefferies GroupDowngradeBuy -> Hold$149.00 -> $173.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2015MizuhoBoost Price TargetNeutral$158.00 -> $173.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2015Cantor FitzgeraldDowngradeBuy -> Hold$151.00 -> $158.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015Piper Jaffray Cos.DowngradeOverweight -> Neutral$160.00 -> $158.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2015Sterne Agee CRTDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Deutsche Bank AGReiterated RatingHold$107.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Goldman Sachs Group Inc.Reiterated RatingHOLD$111.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Credit Suisse Group AGBoost Price TargetNeutral$111.00 -> $121.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2014Canaccord GenuityBoost Price TargetBuy$117.00 -> $147.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Roth CapitalDowngradeBuy -> Neutral$155.00 -> $95.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Stifel NicolausDowngradeBuy -> Hold$185.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014William BlairDowngradeOutperform -> Market Perform$184.00 -> $89.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/20/2014JMP SecuritiesReiterated RatingMarket Outperform$173.00 -> $190.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Keefe, Bruyette & WoodsReiterated RatingOutperform$160.00 -> $147.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Salix Pharmaceuticals (NASDAQ:SLXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
3/2/2015Q414($0.29)($2.61)$187.97 million$13.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$1.56$1.53$394.00 million$354.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$1.69$1.59$397.06 million$382.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114$0.91$1.05$372.91 million$384.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413$0.93$1.06$247.29 million$257.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313$0.86$0.89$239.70 million$238.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013$0.81$0.87$226.34 million$235.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013$0.67$0.63$205.94 million$202.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q4 2012$0.78$0.81$199.41 million$198.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312$0.69$0.95$187.23 million$185.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012$0.54$0.79ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2012$0.56$0.67ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2011$0.60$0.77ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2011$0.44$0.32ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011$0.17$0.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2011$0.49$0.66ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Salix Pharmaceuticals (NASDAQ:SLXP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Salix Pharmaceuticals (NASDAQ:SLXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Salix Pharmaceuticals (NASDAQ:SLXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/6/2015Timothy J CreechInsiderSell4,600$157.67$725,282.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2015William P ForbesEVPSell20,000$157.96$3,159,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014William P ForbesEVPSell11,079$95.05$1,053,058.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014Carolyn J LoganCEOSell53,057$123.38$6,546,172.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2014Alonzo Thomas DDirectorSell11,530$110.89$1,278,561.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Alonzo Thomas DDirectorSell12,050$91.83$1,106,551.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/9/2014Adam DerbyshireCFOSell30,001$91.48$2,744,491.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014William ForbesEVPSell8,000$90.06$720,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014Rick ScruggsEVPSell8,463$88.31$747,367.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2014William KeaneDirectorSell22,500$88.31$1,986,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/24/2013William P ForbesEVPSell12,000$70.93$851,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2013William P ForbesEVPSell8,673$49.37$428,186.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2012Adam C DerbyshireCFOSell60,000$41.44$2,486,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2012Mark A SirgoDirectorSell3,450$40.53$139,828.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Salix Pharmaceuticals (NASDAQ:SLXP)
DateHeadline
07/26/16 09:51 AMNew Broker Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ ... - FTSE News
07/20/16 12:50 PMValeant gets new approval for legacy Salix drug -
07/20/16 11:30 AMValeant's Drug Approvals May Save the Day -
07/20/16 08:21 AMValeant Scores 'Vindicating Win' as 2 Key Drugs Clear FDA Hurdles -
07/17/16 10:30 AMNext Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Fiscal Standard
06/28/16 06:19 PMSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Updated Price Targets - FTSE News
06/24/16 06:32 PMSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Current Analyst Ratings - Fiscal Standard
06/17/16 01:41 PMHow Much Is Valeant Pharmaceuticals Really Worth? -
06/11/16 09:25 AMPfizer Drug Prices Rise By 8.8% Average - PharmaLive (press release) (subscription)
06/10/16 02:43 PMDoctors Who Prescribed Salix Drugs Ate Well -
06/10/16 10:55 AMDetails of kickbacks and fraud emerge in Valeant's Salix unit settlement -
06/10/16 07:56 AMValeant (VRX) Stock Slides on $54 Million Settlement -
06/09/16 04:45 PMValeant pays $54 million to settle U.S. kickback, fraud claims - [Reuters] - Valeant Pharmaceuticals International Inc will pay $54 million to settle civil charges that its Salix unit paid illegal kickbacks to induce doctors to prescribe seven of its products, causing the submission of thousands of fraudulent reimbursement claims to the U.S. government. The accord announced on Thursday by the U.S. Department of Justice covers alleged improper activity at the former Salix Pharmaceuticals Inc from 2009 to 2013, predating its April 2015 acquisition by Valeant for more than $11 billion. Salix admitted and accepted responsibility for routinely paying doctors hundreds or thousands of dollars, or offering perks including lavish meals at restaurants such as Le Bernardin and Nobu, to attend some of its roughly 10,000 "speaker programs," including many with little or no educational value.
06/09/16 04:43 PMValeant pays $54 mln to settle U.S. kickback, fraud claims - [Reuters] - Valeant Pharmaceuticals International Inc will pay $54 million to settle civil charges that its Salix unit paid illegal kickbacks to induce doctors to prescribe seven of its products, causing the submission of thousands of fraudulent reimbursement claims to the U.S. government. The accord announced on Thursday by the U.S. Department of Justice covers alleged improper activity at the former Salix Pharmaceuticals Inc from 2009 to 2013, predating its April 2015 acquisition by Valeant for more than $11 billion. Salix admitted and accepted responsibility for routinely paying doctors hundreds or thousands of dollars, or offering perks including lavish meals at restaurants such as Le Bernardin and Nobu, to attend some of its roughly 10,000 "speaker programs," including many with little or no educational value.
06/09/16 03:38 PMValeant Unit Settles Claims of Pushing Drugs With Pricey Dinners -
06/09/16 02:58 PMU.S. joins whistleblower lawsuit against Valeant's Salix unit - [Reuters] - The U.S. government has joined a whistleblower lawsuit accusing the Salix unit of Valeant Pharmaceuticals International Inc of paying illegal kickbacks to doctors to induce them to prescribe its products, ...
06/08/16 11:35 AMValeant pays $47M to settle 2013 DOJ investigation into legacy Salix drugs -
05/26/16 12:11 PMBiotech: 2 Attractive Buyout Targets For Under $7 A Share - Seeking Alpha - Seeking AlphaBiotech: 2 Attractive Buyout Targets For Under $7 A ShareSeeking AlphaOver the last week both Anacor Pharmaceuticals (NASDAQ:ANAC) and XenoPort (NASDAQ:XNPT) were acquired. Both were taken out for 55% to 60% premiums as well, showing how cheap some of the small- and mid-cap names have gotten in this sector ...
05/16/16 09:42 AMSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Broker Price Targets For The Coming Week - Share Trading News - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). The latest reports which are currently in issue on Sunday 15th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
04/22/16 05:24 PMSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Latest Broker Views - Risers & Fallers - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 ...
04/19/16 05:31 PMBiomerica - Growing Revenue, Solid Balance Sheet And Potentially Significant Upside From IBS Test - Seeking Alpha - Biomerica - Growing Revenue, Solid Balance Sheet And Potentially Significant Upside From IBS TestSeeking AlphaThe resurgence in Europe could be a catalyst to the steepening of the revenue curve. IBS test candidate InFoods still under development could be a big winner. Initial IP filed. InFoods would be the first IBS test to both diagnose the condition and to ...
04/12/16 10:30 PMRecently Changed Price Targets On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers - Recently Changed Price Targets On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)Risers & Fallers02/24/2015 – Salix Pharmaceuticals, Ltd. was downgraded to “hold” by analysts at Cantor Fitzgerald. They now have a USD 151 price target on the stock. 02/23/2015 – Salix Pharmaceuticals, Ltd. had its “neutral” rating reiterated by analysts at Susquehanna.and more »
04/08/16 05:29 PMSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Latest Broker Coverage - Risers & Fallers - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). According to the latest broker reports outstanding on Friday 8th of April, 0 analysts have a rating of “strong buy”, 0 ...
04/07/16 05:36 PMSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Analyst Review - Risers & Fallers - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Analyst ReviewRisers & FallersA number of investment brokers have recently updated their price targets on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). According to the latest broker reports outstanding on Thursday 7th of April, 0 analysts have a rating of “strong buy”, 0 ...and more »
04/05/16 03:30 PMReport: Valeant cutting Addyi sales force -
04/04/16 05:17 PMLatest Analyst Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Share Trading News - Latest Analyst Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)Share Trading News02/24/2015 – Salix Pharmaceuticals, Ltd. had its “neutral” rating reiterated by analysts at UBS. They now have a USD 158 price target on the stock. 02/24/2015 – Salix Pharmaceuticals, Ltd. was downgraded to “hold” by analysts at Cantor Fitzgerald. They ...and more »
04/03/16 04:47 PMNext Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Share Trading News - Next Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)Share Trading News03/18/2015 – Salix Pharmaceuticals, Ltd. was downgraded to “hold” by analysts at Jefferies. They now have a USD 173 price target on the stock. 03/16/2015 – Salix Pharmaceuticals, Ltd. had its “neutral” rating reiterated by analysts at Mizuho. They now ...
03/28/16 09:53 PMThis Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Share Trading News - This Weeks Broker Price Targets For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)Share Trading News02/24/2015 – Salix Pharmaceuticals, Ltd. had its “neutral” rating reiterated by analysts at UBS. They now have a USD 158 price target on the stock. 02/24/2015 – Salix Pharmaceuticals, Ltd. was downgraded to “hold” by analysts at Cantor Fitzgerald. They ...and more »
03/23/16 10:02 PMSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Broker Updates - Risers & Fallers - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Broker UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). According to the latest broker reports outstanding on Wednesday 23rd of March, 0 analysts have a rating of “strong buy”, ...
03/22/16 04:58 PMNew Broker Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - FTSE News - New Broker Ratings For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)FTSE News11/07/2014 – Salix Pharmaceuticals, Ltd. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 150 price target on the stock. The share price of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) was up +0.00% during the last trading ...
03/21/16 07:59 AMAtlantic Healthcare closes $24 million financing with founders of Salix Pharmaceuticals and Clinigen Group, and LDC - Business Wire (press release) - Atlantic Healthcare closes $24 million financing with founders of Salix Pharmaceuticals and Clinigen Group, and LDCBusiness Wire (press release)Dr. Lorin K Johnson was previously the Scientific Founder of Salix Pharmaceuticals, Inc. (NASDAQ: SLXP) until its $15.8 billion acquisition in April 2015 by Valeant Pharmaceuticals International, Inc. Prior to Salix, Dr. Johnson was Chief Scientist at ...and more »
03/17/16 05:12 PMBMO Still Believes Valeant Is Undervalued - Benzinga - BMO Still Believes Valeant Is UndervaluedBenzingaAround the same time last year, management had indicated that 2016 EBITDA would be at least $7.5Bn, was emphasizing that, after the acquisition of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Valeant has now reduced its guidance to $5.6-$5.8Bn ...and more »
03/15/16 03:55 PMRevenue from Salix drug lower than Valeant expected -
03/15/16 11:36 AMValeant missed huge on its 'billion dollar' savior drug — that should raise a big red flag -
03/15/16 09:25 AMHow Salix/Sprout affected Valeant's earnings -
03/07/16 10:08 PMSalix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Updated Price Targets - Share Trading News - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Updated Price TargetsShare Trading News03/18/2015 – Salix Pharmaceuticals, Ltd. was downgraded to “hold” by analysts at Jefferies. They now have a USD 173 price target on the stock. 03/16/2015 – Salix Pharmaceuticals, Ltd. had its “neutral” rating reiterated by analysts at Mizuho. They now ...and more »
02/29/16 02:39 PMValeant Says It's Under Investigation by SEC, Shares Plunge -
02/23/16 04:35 PMWhere Salix fits in Valeant’s earnings restatement -
02/23/16 08:07 AMValeant Has Risk Of New Undisclosed SEC Probe, Report Says -
02/18/16 08:44 AMPrice Target Update On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers - Price Target Update On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). Most recent broker ratings. 03/18/2015 – Salix Pharmaceuticals, Ltd. was downgraded to “hold” by analysts at Jefferies.
02/10/16 11:33 AMSEC Investigating Ex-Salix Executives Over Misleading Investors - Reuters reported on Tuesday that the U.S. Securities and Exchange Commission is investigating former top executives at Salix Pharmaceuticals over allegedly misleading investors. The investigation focuses on Salix's 2014 disclosure that its drug inventory levels were higher than previously reported. Reuters added that it's unclear if any civil charges will be made ...Full story available on Benzinga.com
02/09/16 05:15 PMSEC investigating former Salix Pharma execs, Reuters reports -
02/09/16 02:23 PMSEC probes former Salix CEO, CFO over investor disclosure-source - WASHINGTON, Feb 9 (Reuters) - U.S. securities regulators are investigating whether former top executives at Salix Pharmaceuticals misled investors in connection with the company's 2014 disclosure...
02/08/16 03:33 PMRecent Broker Updates On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers - Recent Broker Updates On Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). The latest broker reports which are currently outstanding on Monday 8th February state 0 analysts have a rating of “strong buy”, ...
02/03/16 08:11 AMValeant Accused of Hiding Cold Drug Study Results Proving Drug Was No More Effective than a Placebo - PharmaLive (press release) (subscription) - Valeant Accused of Hiding Cold Drug Study Results Proving Drug Was No More Effective than a PlaceboPharmaLive (press release) (subscription)The company, in April, bought two cardiac drugs, Nitropress and Isupress, when it acquired Salix Pharmaceuticals (SLXP). ... So the news has almost very limited impact on actual drug spending, but it's a great way for Express Scripts to send a signal.”.and more »
01/29/16 08:17 AMAnalyst Coverage Updates - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers - Analyst Coverage Updates - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). The latest broker reports which are currently outstanding on Friday 29th January state 0 analysts have a rating of “strong buy”, ...and more »
01/28/16 03:09 PMPershing Square's Bill Ackman Writes Letter of Apology to Investors, Regrets Investing so Heavily into Valeant - PharmaLive (press release) (subscription) - Pershing Square's Bill Ackman Writes Letter of Apology to Investors, Regrets Investing so Heavily into ValeantPharmaLive (press release) (subscription)The company acquired rights to two cardiac drugs, Nitropress and Isuprel, when it bought Salix Pharmaceuticals, Ltd. (SLXP). Valeant then increased the prices for those drugs by 212 percent and 525 percent, respectively. Despite the issues over the ...and more »
01/19/16 07:52 AMBroker Update For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) - Risers & Fallers - Broker Update For Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)Risers & FallersBelow are the most recently updated broker updates which include ratings and price targets for Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). 03/18/2015 – Broker: Jefferies Rating: hold New Target: 173 downgrade. 03/16/2015 – Broker: Mizuho Rating: ...
05/16/15 06:49 PMJohn Paulson Buys Actavis, AIG, Valeant, Sells Equinix, Alibaba -
05/15/15 03:45 PMBig name investors take sides on Ackman bet on Valeant: filings -

Social

About Salix Pharmaceuticals

Salix Pharmaceuticals logoSalix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SLXP
  • CUSIP: 79543510
Key Metrics:
  • Previous Close: $169.00
  • 50 Day Moving Average: $173
  • 200 Day Moving Average: $133
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $4 EPS
  • Next Year EPS Consensus Estimate: $9 EPS
Additional Links:
Salix Pharmaceuticals (NASDAQ:SLXP) Chart for Friday, July, 29, 2016